scholarly journals BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS

2021 ◽  
Vol 20 (4) ◽  
pp. 116-121
Author(s):  
A. R. Bosieva ◽  
M. V. Ermoshchenkova ◽  
N. N. Volchenko ◽  
A. D. Zikiryahodjaev
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Disease Free Survival ◽  
Breast Conserving Surgery ◽  
Oncologic Outcomes ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Margin Width

The purpose of the study was to present the most recent data on the outcomes of breast-conserving surgery after neoadjuvant chemotherapy for breast cancer patients.Material and methods. We analyzed relevant publications available in the pubmed, cochrane library, e-library databases between 1990 and 2020, and 24 of them were used to write this review.Results. Neoadjuvant chemotherapy for breast cancer patients is currently a widespread treatment option. The main advantage of this type of treatment for patients with early stage breast cancer is the feasibility of performing breast-conserving surgery in cases of partial or complete clinical response and, therefore, the improvement of the quality of life of patients with equivalent rates of disease-free survival compared to radical mastectomies.Conclusion. Numerous studies have shown that breast-conserving surgery following neoadjuvant chemotherapy is the safe surgery with good oncologic outcomes and an alternative to radical mastectomies in breast cancer patients. However, further studies are required to determine the optimal safe resection margin width in patients with complete and partial responses to neoadjuvant chemotherapy.

scholarly journals The Neutrophil–Lymphocyte Ratio has Little Impact on Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery

2021 ◽  
Author(s):  
Katsuhisa Enomoto ◽  
Satsuki Fukumoto ◽  
Hironori Goto ◽  
Satoshi Mori ◽  
Yukiko Hara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Disease Free

Abstract Background: The impact of the neutrophil–lymphocyte ratio (NLR) on the survival outcomes of patients with early-stage breast cancer is controversial. Methods: We reviewed a series of 115 breast cancer patients who received neoadjuvant chemotherapy followed by surgical treatment. The NLR was calculated using a blood sample obtained before neoadjuvant chemotherapy. The relationships of disease-free survival with the NLR as well as other clinicopathological factors were assessed.Results: There was no significant association between the NLR and disease-free survival in these patients. On the other hand, negative estrogen receptor and progesterone receptor statuses, extended nodal involvement, and advanced TNM stage were significant predictors of shorter disease-free survival.Conclusions: The NLR has little impact on the survival of early-stage breast cancer patients treated with neoadjuvant chemotherapy followed by surgical treatment.

scholarly journals Postmastectomy radiotherapy after neoadjuvant chemotherapy in cT1-2N+ breast cancer patients: a single center experience and review of current literature

2022 ◽  
Author(s):  
Meng Luo ◽  
Huihui Chen ◽  
Hao Deng ◽  
Yao Jin ◽  
Gui Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Cox Regression ◽  
Medical Center ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Her2 Overexpression ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract PurposePostmastectomy radiotherapy (PMRT) after NAC in breast cancer patients with initial clinical stage cT1−2N+, especially for those who achieved ypT1−2N0, is still controversial. This study was to evaluate the survival prognosis of cT1−2N+ patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT.Patients and MethodsFrom January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT1−2N+ stage, receiving neoadjuvant chemotherapy (NAC) with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was overall survival, and the secondary endpoint was disease-free survival. Comparison was conducted between PMRT and non-PMRT subgroups.ResultsOf the 215 eligible patients, 35.8% (77/215) cT1−2N+ patients achieved ypT0−2N0 after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT0−2N+). The 5-year DFS of ypT0−2N0 non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT0−2N0 PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT0−2N0 non-PMRT subgroup and cT1−2N0 subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT0−2N+ PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS.ConclusionAn excellent response to NAC (ypT0−2N0) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT1−2N+ breast cancer patients with ypT0−2N0 after NAC.

Sign in / Sign up

Export Citation Format

Share Document